Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival Advantage

Long-term remission is elusive after CD19 chimeric antigen receptor (CAR) T cell therapy for refractory/relapsed CD19+ B cell acute lymphoblastic leukemia (B-ALL) [1 –6]. A high percentage of subjects achieve initial complete remission (CR), but one-half of subjects experience disease recurrence within 6 to 18 months after CAR T cell infusion [1,4,7].

Source: Biology of Blood and Marrow Transplantation - October 10, 2021 Category: Hematology Authors: Corinne Summers, Qian Vicky Wu, Colleen Annesley, Marie Bleakley, Ann Dahlberg, Prabha Narayanaswamy, Wenjun Huang, Jenna Voutsinas, Adam Brand, Wendy Leisenring, Michael C. Jensen, Julie R. Park, Rebecca A. Gardner Source Type: research